EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polyendocrine Metabolic Ovarian Syndrome (PMOS) and Dermatological Manifestations: Association of Hyperandrogenism, Acne, Hirsutism, and Metabolic Dysfunction

Sohel Ahammed, Abdus Sattar, Mohsina Haider, Naznin Akter Zahan

Naogaon Medical College Journal · 10.11.2026 · 3 (2) · 133-144

DOI: 10.70818/nmcj.v03i02.099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naogaon Medical College Journal, online erschienen am 10.11.2026. Verfasst von Sohel Ahammed und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polyendocrine metabolic ovarian syndrome (PMOS, formerly polycystic ovary syndrome) often presents to dermatologists with acne, hirsutism and hair loss. Their relationship to metabolic dysfunction is poorly described in South Asia.

Objective

To describe cutaneous and metabolic features in patients with PMOS and to examine associations among hyperandrogenism, acne, hirsutism, female pattern hair loss (FPHL), acanthosis nigricans and metabolic syndrome.

Methods

Hospital-based observational study (cross-sectional baseline, six-month treatment follow-up), Department of Dermatology, Kushtia Medical College, January 2025 to June 2026. Records of 182 patients aged 18 to 52 years were analysed. Proportions are given with Wilson 95% confidence intervals; associations were tested with Fisher's exact test (Holm-adjusted) and multivariable logistic regression.

Results

Hirsutism (modified Ferriman-Gallwey score ≥8) occurred in 78.0%, acne in 76.4% (moderate to severe 46.7%), acanthosis nigricans in 66.5% and FPHL in 33.5%. Metabolic syndrome was recorded in 46.7% and 81.9% were overweight or obese. Metabolic syndrome was associated with obesity (OR 9.05, 95% CI 4.48 to 18.30) and BMI (adjusted OR 1.67 per kg/m², 1.43 to 1.95), but not with hirsutism, acne, hyperandrogenism or FPHL. Hyperandrogenism and FPHL were associated before multiplicity adjustment only (OR 2.70, 1.16 to 6.25; Holm p = 0.38). At six months 62.1% had significant improvement, with no difference between treatment protocols (p = 0.93); 1.6% had a recorded complication.

Conclusions

In this cohort, skin phenotype did not discriminate metabolic status, whereas adiposity did. Metabolic assessment appears warranted irrespective of skin presentation. The absent comparison group and unverified case definitions limit inference.

Zitieren

APA

Ahammed, S., Sattar, A., Haider, M., & Zahan, N. A. (2026). Polyendocrine Metabolic Ovarian Syndrome (PMOS) and Dermatological Manifestations: Association of Hyperandrogenism, Acne, Hirsutism, and Metabolic Dysfunction. Naogaon Medical College Journal, 3(2), 133-144. https://doi.org/10.70818/nmcj.v03i02.099

Vancouver

Ahammed S, Sattar A, Haider M, Zahan NA. Polyendocrine Metabolic Ovarian Syndrome (PMOS) and Dermatological Manifestations: Association of Hyperandrogenism, Acne, Hirsutism, and Metabolic Dysfunction. Naogaon Medical College Journal. 2026;3(2):133-144. doi:10.70818/nmcj.v03i02.099

BibTeX
@article{Ahammed2026,
  author = {Ahammed, Sohel and Sattar, Abdus and Haider, Mohsina and Zahan, Naznin Akter},
  title = {Polyendocrine Metabolic Ovarian Syndrome (PMOS) and Dermatological Manifestations: Association of Hyperandrogenism, Acne, Hirsutism, and Metabolic Dysfunction},
  journal = {Naogaon Medical College Journal},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {133--144},
  doi = {10.70818/nmcj.v03i02.099}
}
Kostenlos starten →